People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Biotechnology, Software / Tech, Pharmaceuticals, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Juvenescence Ltd | — | Biotechnology | Series C | $121.9M | $324.6M | 2017 |
| Liberation Labs Holdings Inc. | — | Software / Tech | Series C | $121.2M | $368.0M | 2022 |
| AlphaTON Capital Corp | — | Pharmaceuticals | Series B | $70.7M | $158.9M | 2025 |
| Insilico Medicine Cayman TopCo | — | Biotechnology | Series B | $36.8M | $1.5B | 2019 |
| LyGenesis Inc. | — | Biotechnology | Series B | $25.8M | $174.1M | 2020 |
| Polo Resources Ltd | — | Other | Series A | $13.2M | $151.3M | 2009 |
| Insilico Medicine, Inc. | — | Biotechnology | Series A | $12.8M | $216.9M | 2018 |
| Brazilian Gold Corp | — | Other | Series A | $7.5M | $114.0M | 2011 |
| New Agrarian Co Ltd | — | Other | Seed | $2.0M | $2.2M | 2022 |
| SalvaRx Group plc | — | Biotechnology | Pre-Seed | $340K | $18.8M | 2016 |
James Mellon at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside James Mellon on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Gregory Bailey | 4 | 8 |
| Denham Eke | 2 | 4 |
| Philip Boigner | 2 | 2 |
| Declan Doogan | 1 | 6 |
| Robert Kramer | 1 | 5 |
| Alvin Jackson | 1 | 5 |
| Jim Mellon | 1 | 4 |
| Stephen Dattels | 1 | 4 |
| STEVEN FINN | 1 | 4 |
| Thomas Hudson | 1 | 4 |
| Guy Elliot | 1 | 3 |
| Steven Mintz | 1 | 3 |
| Garnet Dawson | 1 | 3 |
| Ian Walters | 1 | 3 |
| Glen Dickson | 1 | 3 |
| David Roblin | 1 | 3 |
| Guy Elliott | 1 | 3 |
| Anthony Chow | 1 | 2 |
| John Stalker | 1 | 2 |
| Michael Hufford | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.